| Literature DB >> 34634961 |
Malia Duffy1, Anna Ghosh1, Ana Geltman1, Gabriel Kieto Mahaniah1, Molly Higgins-Biddle1, Michele Clark1.
Abstract
Individuals who have HIV who also use drugs experience increased age-matched morbidity and mortality in comparison with those with HIV who do not use drugs. A systematic review was conducted to describe models of integrated HIV and opioid use disorder (OUD) services, enablers of and barriers to integrated service access, and the coordinated systems and tools at the state and service delivery levels required for implementation. Database searches yielded 235 candidate articles, of which 22 studies met the inclusion criteria. Analysis found that integrated programs operated with minimal coordinated policy and systems guidance at the state level. Service delivery systems and tools used for integration, including use of integrated protocols, risk assessment tools, case management tools, and referral systems, were similar across integration models. Concerted efforts to coordinate state-level systems and develop supportive policies, guidelines, and standardized tools may facilitate integration at the service delivery level.Entities:
Keywords: HIV; opioid use disorder; service access; service integration; substance use; systems coordination
Mesh:
Year: 2021 PMID: 34634961 PMCID: PMC9397399 DOI: 10.1177/10775587211051182
Source DB: PubMed Journal: Med Care Res Rev ISSN: 1077-5587 Impact factor: 2.971
Definitions.
Figure 1.Conceptual Framework to Influence HIV/OUD Clinical Care Coordination.
Note. OUD = opioid use disorder.
Figure 2.PRISMA Flowchart of Study Selection.
Summary of Integrated HIV and OUD Programs From Included Studies.
| Authors | Study design and description | Study population | Model | Enablers of/barriers to service access | Associated outcomes and conclusions |
|---|---|---|---|---|---|
|
| Retrospective cohort study in a Virginia Outpatient RWHAP clinic examined the role of co-located mental health and substance use counseling among people with HIV. The clinic received funding to hire an on-site certified psychologist and substance use counselor. | HIV service integration models | Among patients who were newly introduced to integrated services, viral load suppression increased from 57% before to 88% in the year after integration ( | ||
|
| Qualitative study to understand how people with HIV who were previously accessing integrated HIV and behavioral health/substance use services at integrated RWHAP clinics in California navigated the health care system following Medicaid expansion, which resulted in clients being required to access off-site substance use and HIV services. | HIV service integration models | Medicaid expansion can increase access to substance use services for people with HIV. However, it can also increase the risk of care fragmentation in multi-payer systems. | ||
|
| Retrospective evaluation of treatment outcomes among all clients enrolled in outpatient Stabilization, Treatment, and Engagement Program within an urban community-based syringe exchange program in Philadelphia, PA. | OUD service integration models | Among the 124 patients, 23% had unplanned self-discharge and 15% were administratively discharged for drug diversion or failure to progress. The % of patients retained in buprenorphine maintenance treatment at 3, 6, 9, and 12 months were 77%, 65%, 59%, and 56%, respectively. | ||
|
| Microsimulation study comparing the cost-effectiveness of two approaches to managing OUD treatment among HIV/HCV co-infected clients who are being considered for HCV treatment: (a) standard HIV care with on-site HCV treatment and referral to off-site OUD care (status quo); and (b) standard HIV care with on-site HCV and buprenorphine and naltrexone treatment (integrated care). | Not applicable | HIV service integration models | Not applicable | Integrated care reduced HCV reinfections by 7%; cases of cirrhosis by 1%; and liver-related deaths by 3%. Compared with the status quo, this strategy also resulted in an estimated 11/1,000 fewer non-liver attributable deaths at 1 year and 28/1,000 fewer of these deaths at 5 years, at a cost-effectiveness ratio of $57,100/QALY. |
|
| Mixed-methods study consisting of qualitative information collected from a technical expert panel of 13 RWHAP funded recipients and data analysis of RWHAP Services report 2010–2017 to understand client characteristics and service utilization among RWHAP clients who also access substance use services. | 13 RWHAP funded recipients | HIV service integration models | Addressing system challenges, including reimbursement issues, providing community-level leadership that supports integrated care, and increasing availability of naltrexone-based MAT and buprenorphine through addressing waiver requirements will help to end the HIV epidemic. | |
|
| Secondary analysis of the 2011 SAMHSA National Survey of Substance Abuse Treatment Services. The study examined a national sample of substance use treatment facilities to determine whether they provided testing, early intervention; education, counseling, or support; specially designed substance use treatment program/group exclusively for people with HIV. | OUD service integration models | Among substance use treatment facilities, 28% offered HIV testing; 26% offered early intervention; 58% offered HIV education, counseling, or support; and 8% offered special programs. | ||
|
| This randomized trial introduced a personal contact intervention and evaluated whether heavy alcohol or illicit drug use were modifiers of client retention | HIV service integration models | More intense and frequent contact with people who use substances enrolled in HIV services improves retention in care. | ||
|
| Observational cohort study in outpatient Ryan White Part A-funded medical case management program in New York City. Examined whether case management reduces psychosocial barriers such as unstable housing and substance use, and the effect of that on HIV care engagement and viral suppression outcomes. | HIV service integration models | Among clients identified as having unstable housing at baseline, there was a noted longer engagement in care and viral suppression among individuals receiving integrated services. | ||
|
| Policy and practice evaluation that examined written policies in methadone maintenance treatment (MMT) programs in Philadelphia in 2015 and compared them with a 2010 audit, and compared the differences in how the programs tested for HCV and HIV. | 2010: 12 MMT programs with 5,900 patients in Philadelphia. | OUD service integration models | MMT programs are positioned to mitigate the HIV and HCV epidemics. To do so, they require guidance, training, and financial support. | |
|
| Mixed-methods qualitative/quantitative study describes integration of HIV services into buprenorphine treatment and examines whether the type of HIV services vary by buprenorphine-prescribers’ medical specialty and across practice settings. | OUD service integration models | Only 1/3 of the 1,174 waivered providers offered on-site testing services. Only 50% recommend to new clients that they receive HIV testing services. Many buprenorphine prescribers see HIV testing as outside their scope of practice. | ||
|
| Randomized controlled trial at inpatient HIV clinical visits Vancouver, BC, Canada, and Chicago, IL, United States, that aimed to compare (a) extended-release naltrexone (XR-NTX) treatment initiation, (b) retention, and (c) safety of XR-NTX vs. treatment as usual (TAU) for OUD and/or alcohol use disorder in HIV clinics. | HIV service integration models | 88% of those receiving XR-NTX were retained at 15 weeks in comparison with 50% receiving TAU. Among those with OUD, HIV viral suppression increased from 67% to 80% for XR-NTX and 58% to 75% for TAU. | ||
|
| Qualitative study in New Haven and Danbury, CT, including three federal health centers that offer both HIV and OUD services; two specialty hospital-based HIV clinics; and seven OTPs. Examined factors that influence care integration for HIV and OUD. | Both HIV and OUD service integration models | Challenges to implement integrated care include mismatches in resources allocated to HIV and OUD programs, which resulted in differential access to HIV vs. OUD services. Institutional policies also reduce integrated access (e.g., requiring an HIV provider’s signature for an ART refill, but not having an HIV provider on site). | ||
|
| Program description of an OTP in WA state that explored policies required to provide clients with uninterrupted methadone during COVID-19 with considerations for clients with HIV. | Not applicable | OUD service integration models | The program was granted modified eligibility requirements, which increased the amount of take-home dosing for people with HIV, which reduced the need for vulnerable clients to physically access services during the pandemic. | |
|
| Qualitative study examining HIV risk perceptions, pre-exposure prophylaxis (PrEP) awareness and interest among people formerly incarcerated in the RI prison system and enrolled in a structured MAT program. | OUD service integration models | Overall, 59% ( | ||
|
| Data analysis of the Buprenorphine-HIV Evaluation and Support Collaborative data set. The study examined whether prior incarceration among patients receiving buprenorphine treatment during HIV care led to a difference in HIV treatment retention and opioid use outcomes. | HIV service integration models | Did not detect significant differences in self-reported opioid use, 6-month, or 12-month retention in buprenorphine treatment among those who had been incarcerated vs. those who had not. | ||
|
| Mixed-methods with quantitative survey and qualitative interviews among clients from outpatient and community settings in San Francisco, CA. Aim was to examine (a) the impact of substance use issues on ART adherence among youth with HIV; (b) barriers to substance counseling and treatment; and (c) how technology can be used for the provision of these services. | HIV service integration models | Youth with HIV overwhelmingly said that videoconferencing is convenient, efficient, and private, and is less intimidating than in-person substance use and mental health counseling sessions. | ||
|
| Retrospective chart review from an outpatient university-affiliated HIV clinic in AL that examined the association between mental health service use (including substance use counseling) and retention in HIV primary medical care. | HIV service integration models | 17% of HIV clients screened positive for current substance use. Individuals who received integrated services were more likely to be retained in care. | ||
|
| Mixed-methods study in an inner-city MMT program in New Haven, CT. Consisted of qualitative and quantitative interviews that examined the use of PrEP and related experiences and attitudes among PWUD. | OUD service integration models | PrEP was integrated within an MMT program among people who use drugs. Absence of out-of-pockets costs related to PrEP facilitated its uptake. | ||
|
| Pre-/post-test follow-up study to assess efficacy of the Bio-Behavioral Community-friendly Health Recovery Program (CHRP-BB) intervention, a theory-driven manual-guided intervention comprising four 50-min weekly group meetings that address HIV risk behaviors and PrEP adherence among high-risk people who use drugs (PWUD) in treatment. | OUD service integration models | PrEP adherence and knowledge significantly improved and persisted 1 month following the intervention. Drug-related risk behaviors significantly reduced by the end of the intervention and remained reduced at the 4 week post-intervention follow-up. Significant HIV behavior risk reductions were identified immediately post-intervention and remained reduced at the 4 week follow-up. | ||
|
| Mixed-methods participant assessment, cost-effectiveness analysis of a brief bio-behavioral intervention to promote PrEP adherence and reduce HIV risk among PWUD through comparisons of controlled and modified randomized groups in a New Haven area including a jail setting. | OUD service integration models | Increase PrEP adherence and HIV risk reductions among participants were found among clients receiving the intervention. | ||
|
| Retrospective quantitative analysis that included a review of electronic medical record data from 2015 for all patients with known HIV at the opioid treatment outpatient program (OTOP) at a large safety net hospital in San Francisco, CA. The study examined client outcomes based on the OTOP HIV Care Continuum, and retention and viral suppression in patients receiving HIV care at OTOP in comparison with HIV specialty or community clinics. | OUD service integration models | High rates of retention in HIV care (77%) and viral suppression (80%) for those who received HIV care at the methadone clinic. Retention and viral suppression were highest for patients receiving care at the methadone clinic in comparison with the specialty HIV and other community clinics. | ||
|
| Survey of clients admitted to New York Bellevue Hospital’s inpatient detoxification program explored (a) technology use patterns and (b) preferences for adopting health information technologies to enhance self-management and peer-driven approaches to addiction treatment, HIV, and HCV care. | OUD service integration models | Text and telephone messages on addiction, HIV, and HCV care are highly acceptable, particularly among those who reported recent homelessness, incarceration, and less than a high school education. Findings demonstrate the potential for health information technology to provide integrated health messaging among populations who are vulnerable to HIV, HCV, and substance use disorder. |
Note. OUD = opioid use disorder; RWHAP = Ryan White HIV/AIDS Program; HCV = hepatitis C virus; MAT = medications for addiction treatment; OTP = opioid treatment program; ART = antiretroviral treatment; COVID-19 = coronavirus disease-2019; LGBTQ = lesbian, gay, bisexual, transgender, and questioning; QALY = quality adjusted life year; SAMHSA = Substance Abuse and Mental Health Services; PWUD = people who use drugs.
Systems Components Used Within the Integrated Models.
| Model | Service entry point | Integrated service(s) | Human resources required | Systems and tools used across the models |
|---|---|---|---|---|
| OUD Service Integration | Outpatient OUD treatment | • PrEP | • Clinicians | • Referral systems and tools for HIV care and treatment, PrEP, and psychosocial services |
| SSP | • HIV, HCV testing (and referral) | • Case managers, medical director, medical students, and residents | ||
| Inpatient detox program | • Health messages on addiction and HIV, HCV care | • No information provided | ||
| MAT prison program | • PrEP | • Counselors | ||
| HIV Service Integration | HIV care and treatment programs | • SU screen with referral | • HIV primary care clinicians (including physicians and nurse practitioners) | • Separate space within HIV clinics that provides privacy for SU counseling |
Note. OUD = opioid use disorder; PrEP = pre-exposure prophylaxis; HCV = hepatitis C virus; ART = antiretroviral treatment; MAT = medications for addiction treatment; RWHAP = Ryan White HIV/AIDS Program; SSP = syringe service program; SU = substance use.
EPHPP Quality Assessments for Quantitative Studies
| Study |
|
|
|
| |||||
|---|---|---|---|---|---|---|---|---|---|
| Domain | Study team member | M.D. | A.G. | M.D. | A.G. | M.D. | A.G. | M.D. | A.G. |
| Selection bias | Participants representative of target population | Somewhat likely | Somewhat likely | Somewhat likely | Somewhat likely | Very likely | Very likely | Very likely | Very likely |
| Percent of selected individuals who agreed to participate | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| Section rating | Moderate | Moderate | Moderate | Moderate | Moderate | Moderate | Strong | Strong | |
| Study design | Indicate the study design | Cohort analytic | Cohort analytic | Retrospective chart review | Retrospective chart review | Cohort analytic | Cohort analytic | Retrospective RSR data review | Retrospective RSR data review |
| Study described as randomized | No | No | No | No | No | No | No | No | |
| Was randomized method described | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| Was randomized method appropriate | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| Section rating | Moderate | Moderate | Weak | Weak | Moderate | Moderate | Weak | Weak | |
| Confounders | Important differences between groups pre-intervention | Yes | Yes | Can’t tell | Can’t tell | Yes | Yes | Yes | Yes |
| Indicate % of confounders controlled | Most | Most | Can’t tell | Can’t tell | <60% | <60% | Most | Most | |
| Section rating | Strong | Strong | Weak | Weak | Weak | Weak | Strong | Strong | |
| Blinding | Outcome assessors aware of intervention or exposure status of participants | Yes | Yes | Can’t tell | Can’t tell | Yes | Yes | Yes | Yes |
| Participants aware of research question | Can’t tell | Can’t tell | Can’t tell | Can’t tell | Can’t tell | Can’t tell | Can’t tell | Can’t tell | |
| Section rating | Weak | Weak | Moderate | Moderate | Weak | Weak | Weak | Weak | |
| Data collection | Data collection methods valid | Yes | Yes | Yes | Yes | Yes | Yes | Can’t tell | Can’t tell |
| Data collection tools reliable | Yes | Yes | Can’t tell | Can’t tell | Yes | Yes | Can’t tell | Can’t tell | |
| Section rating | Strong | Strong | Moderate | Moderate | Strong | Strong | Weak | Weak | |
| Withdrawals and dropouts | Withdrawals and dropouts reported in #s/reasons per groups | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| % of participants completing the study | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| Section rating | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| Final score | Discrepancy between reviewers (Y/N) | N | N | N | N | N | N | N | N |
| Reason for discrepancy | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
|
|
|
|
|
|
|
|
|
| |
CASP Checklist for Qualitative Studies.
| Reference | Section A: Are the results valid | Section B: What are the results | Section C: Will results help locally | First reviewer | Second reviewer | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
| |||
|
| Yes | Yes | Cannot tell. No justification for research design provided. | Yes | Yes | Cannot tell. No information provided to this effect. | Yes | Yes | Yes | Valuable. The study considers policy implications for research findings. | M.D. | A.S.G. |
|
| Yes | Yes | Yes | Yes | Yes | Yes | Cannot tell. No details of how research was explained to participants. | Yes | Yes | Valuable. Provides guidance for integrated HIV and OUD services. | M.D. | A.S.G. |
|
| Yes | Yes | Cannot tell. No justification for research design provided. | Yes | Yes | Cannot tell. No information provided to this effect. | Yes | Yes | Yes | Valuable. Provides guidance for PrEP integration in criminal justice associated MAT programs. | M.D. | A.S.G. |
Note. CASP = Critical Appraisal Skills Program; OUD = opioid use disorder; MAT = medications for addiction treatment.
| Study |
|
|
|
| |||||
|---|---|---|---|---|---|---|---|---|---|
| Study team member | M.D. | M.D. | M.D. | A.G. | M.D. | A.G. | M.D. | A.G. | |
| Selection bias | Participants representative of target population | Somewhat likely | Somewhat likely | Very likely | Very likely | Very likely | Very likely | Somewhat likely | Somewhat likely |
| Percent of selected individuals who agreed to participate | N/A | N/A | Can’t tell | Can’t tell | N/A | N/A | N/A | N/A | |
| Section rating | Moderate | Moderate | Moderate | Moderate | Moderate | Moderate | Moderate | Moderate | |
| Study design | Indicate the study design | Review of SU Survey | Review of SU Survey | Randomized trial | Randomized trial | Cohort (one group pre and post) | Cohort (one group pre and post) | Audit of methadone survey | Audit of methadone survey |
| Study described as randomized | No | No | Yes | Yes | No | No | No | No | |
| Was randomized method described | N/A | N/A | Yes | Yes | N/A | N/A | N/A | N/A | |
| Was randomized method appropriate | N/A | N/A | Yes | Yes | N/A | N/A | N/A | N/A | |
| Section rating | Weak | Weak | Strong | Strong | Moderate | Moderate | Weak | Weak | |
| Confounders | Important differences between groups pre-intervention | N/A | N/A | Yes | Yes | Yes | Yes | N/A | N/A |
| Indicate % of confounders controlled | N/A | N/A | >80% | >80% | >80% | >80% | N/A | N/A | |
| Section rating | N/A | N/A | Strong | Strong | Strong | Strong | N/A | N/A | |
| Blinding | Outcome assessors aware of intervention or exposure status of participants | Yes | Yes | Can’t tell | Can’t tell | Can’t tell | Can’t tell | Yes | Yes |
| Participants aware of research question | Can’t tell | Can’t tell | Can’t tell | Can’t tell | Can’t tell | Can’t tell | Can’t tell | Can’t tell | |
| Section rating | Weak | Weak | Moderate | Moderate | Moderate | Moderate | Weak | Weak | |
| Data collection | Data collection methods valid | Can’t tell | Can’t tell | Yes | Yes | Yes | Yes | Can’t tell | Can’t tell |
| Data collection tools reliable | Can’t tell | Can’t tell | Yes | Yes | Yes | Yes | Can’t tell | Can’t tell | |
| Section rating | Weak | Weak | Strong | Strong | Strong | Strong | Weak | Weak | |
| Withdrawals and dropouts | Withdrawals and dropouts reported in #s/reasons per groups | N/A | N/A | Can’t tell | Can’t tell | No | No | N/A | N/A |
| % of participants completing the study | N/A | N/A | Can’t tell | Can’t tell | Can’t tell | Can’t tell | N/A | N/A | |
| Section rating | N/A | N/A | Weak | Weak | Weak | Weak | N/A | N/A | |
| Final score | Discrepancy between reviewers (Y/N) | N | N | N | N | N | N | N | N |
| Reason for discrepancy | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
|
|
|
|
|
|
|
|
|
| |
| Study |
|
|
|
| ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Study team member | M.D. | A.G. | M.D. | A.G. | M.D. | A.G. | M.D. | A.G. | ||
| Selection bias | Participants representative of target population | Somewhat likely | Somewhat likely | Very likely | Very likely | Somewhat likely | Somewhat likely | Somewhat likely | Somewhat likely | |
| Percent of selected individuals who agreed to participate | <60% | <60% | 80%–100% | 80%–100% | N/A | N/A | Can’t tell | Can’t tell | ||
| Section rating | Weak | Weak | Strong | Strong | Moderate | Moderate | Moderate | Moderate | ||
| Study design | Indicate the study design | Mixed methods | Mixed methods | Randomized trial | Randomized trial | Cohort | Cohort | Mixed methods (qualitative interviews with surveys) | Mixed methods (qualitative interviews with surveys) | |
| Study described as randomized | Yes | Yes | Yes | Yes | No | No | No | No | ||
| Was randomized method described | Yes | Yes | Yes | Yes | N/A | N/A | N/A | N/A | ||
| Was randomized method appropriate | Yes | Yes | Yes | Yes | N/A | N/A | N/A | N/A | ||
| Section rating | Weak | Weak | Strong | Strong | Moderate | Moderate | Weak | Weak | ||
| Confounders | Important differences between groups pre-intervention | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | |
| Indicate % of confounders controlled | 60%–79% | 60%–79% | <60% | <60% | 80%–100% | 80%–100% | 80%–100% | 80%–100% | ||
| Section rating | Moderate | Moderate | Weak | Weak | Strong | Strong | Strong | Strong | ||
| Blinding | Outcome assessors aware of intervention or exposure status of participants | Yes | Yes | Yes | Yes | Can’t tell | Can’t tell | Yes | Yes | |
| Participants aware of research question | Yes | Yes | Yes | Yes | Can’t tell | Can’t tell | Yes | Yes | ||
| Section rating | Weak | Weak | Weak | Weak | Moderate | Moderate | Weak | Weak | ||
| Data collection | Data collection methods valid | No | No | Can’t tell | Can’t tell | Can’t tell | Can’t tell | Can’t tell | Yes | |
| Data collection tools reliable | Can’t tell | Can’t tell | Can’t tell | Can’t tell | Can’t tell | Can’t tell | Can’t tell | Yes | ||
| Section rating | Weak | Weak | Weak | Weak | Weak | Weak | Weak | Weak | ||
| Withdrawals and dropouts | Withdrawals and dropouts reported in #s/reasons per groups | N/A | N/A | Yes | Yes | Yes | Yes | N/A | N/A | |
| % of participants completing the study | N/A | N/A | 80%–100% | 80%–100% | N/A | N/A | N/A | N/A | ||
| Section rating | N/A | N/A | Strong | Strong | Moderate | Moderate | N/A | N/A | ||
| Final score | Discrepancy between reviewers (Y/N) | N | N | N | N | N | N | N | N | |
| Reason for discrepancy | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||
|
|
|
|
|
|
|
|
|
| ||
| Study |
|
|
|
| ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Study team member | M.D. | A.G. | M.D. | A.G. | M.D. | A.G. | M.D. | A.G. | ||
| Selection bias | Participants representative of target population | Somewhat likely | Somewhat likely | Somewhat likely | Somewhat likely | Not likely | Not likely | Somewhat likely | Somewhat likely | |
| Percent of selected individuals who agreed to participate | Can’t tell | Can’t tell | 80%–100% | 80%–100% | 80%–100% | 80%–100% | N/A | N/A | ||
| Section rating | Moderate | Moderate | Moderate | Moderate | Weak | Weak | Moderate | Moderate | ||
| Study design | Indicate the study design | Retrospective clinical data analysis | Retrospective clinical data analysis | Mixed methods | Mixed methods | Cohort (one group pre and post) | Cohort (one group pre and post) | Randomized controlled trial | Randomized controlled trial | |
| Study described as randomized | No | No | No | No | No | No | Yes | Yes | ||
| Was randomized method described | N/A | N/A | N/A | N/A | N/A | N/A | Yes | Yes | ||
| Was randomized method appropriate | N/A | N/A | N/A | N/A | N/A | N/A | Yes | Yes | ||
| Section rating | Weak | Weak | Weak | Weak | Moderate | Moderate | Strong | Strong | ||
| Confounders | Important differences between groups pre-intervention | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | |
| Indicate % of confounders controlled | 80%–100% | 80%–100% | Can’t tell | Can’t tell | 80%–100% | 80%–100% | 80%–100% | 80%–100% | ||
| Section rating | Strong | Strong | Weak | Weak | Strong | Strong | Strong | Strong | ||
| Blinding | Outcome assessors aware of intervention or exposure status of participants | Can’t tell | Can’t tell | Can’t tell | Can’t tell | Can’t tell | Can’t tell | Can’t tell | Can’t tell | |
| Participants aware of research question | Can’t tell | Can’t tell | Can’t tell | Can’t tell | Can’t tell | Can’t tell | Can’t tell | Can’t tell | ||
| Section rating | Moderate | Moderate | Moderate | Moderate | Moderate | Moderate | Moderate | Moderate | ||
| Data collection | Data collection methods valid | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | |
| Data collection tools reliable | Yes | Yes | Yes | Yes | No | No | Yes | Yes | ||
| Section rating | Strong | Strong | Strong | Strong | Moderate | Moderate | Strong | Strong | ||
| Withdrawals and dropouts | Withdrawals and dropouts reported in #s/reasons per groups | N/A | N/A | N/A | N/A | Yes | Yes | N/A | N/A | |
| % of participants completing the study | N/A | N/A | N/A | N/A | 80%–100% | 80%–100% | N/A | N/A | ||
| Section rating | N/A | N/A | N/A | N/A | Strong | Strong | Strong | Strong | ||
| Final score | Discrepancy between reviewers (Y/N) | N | N | N | N | N | N | N | N | |
| Reason for discrepancy | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||
|
|
|
|
|
|
|
|
|
| ||
| Study |
|
| |||
|---|---|---|---|---|---|
| Study team member | M.D. | A.G. | M.D. | A.G. | |
| Selection bias | Participants representative of target population | Somewhat likely | Somewhat likely | Very likely | Very likely |
| Percent of selected individuals who agreed to participate | N/A | N/A | N/A | N/A | |
| Section rating | Moderate | Moderate | Strong | Strong | |
| Study design | Indicate the study design | Retrospective electronic medical record review | Retrospective electronic medical record review | Survey | Survey |
| Study described as randomized | No | No | No | No | |
| Was randomized method described | N/A | N/A | N/A | N/A | |
| Was randomized method appropriate | N/A | N/A | N/A | N/A | |
| Section rating | Weak | Weak | Weak | Weak | |
| Confounders | Important differences between groups pre-intervention | Yes | Yes | No | No |
| Indicate % of confounders controlled | Yes | Yes | Can’t tell | Can’t tell | |
| Section rating | Strong | Strong | Weak | Weak | |
| Blinding | Outcome assessors aware of intervention or exposure status of participants | N/A | N/A | Can’t tell | Can’t tell |
| Participants aware of research question | N/A | N/A | Can’t tell | Can’t tell | |
| Section rating | N/A | N/A | Moderate | Moderate | |
| Data collection | Data collection methods valid | Yes | Yes | Can’t tell | Can’t tell |
| Data collection tools reliable | Yes | Yes | Can’t tell | Can’t tell | |
| Section rating | Strong | Strong | Weak | Weak | |
| Withdrawals and dropouts | Withdrawals and dropouts reported in #s/reasons per groups | N/A | N/A | N/A | N/A |
| % of participants completing the study | N/A | N/A | N/A | N/A | |
| Section rating | N/A | N/A | N/A | N/A | |
| Final score | Discrepancy between reviewers (Y/N) | N | N | N | N |
| Reason for discrepancy | N/A | N/A | N/A | N/A | |
|
|
|
|
|
| |
Note. EPHPP = Effective Public Health Practice Project; SU = substance use.